Jump to content

Soft-tissue sarcoma: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎Types: refactored tables for row headers, scope="col"/"row"
→‎Notable cases: added citation
(38 intermediate revisions by 24 users not shown)
Line 23: Line 23:
}}
}}


A '''soft-tissue sarcoma''' '''(STS)''' is a [[malignant tumour]], a type of [[cancer]], that develops in [[soft tissue]].<ref name="Ratan">{{cite journal |last1=Ratan |first1=R |last2=Patel |first2=SR |title=Chemotherapy for soft tissue sarcoma. |journal=Cancer |date=October 2016 |volume=122 |issue=19 |pages=2952–60 |doi=10.1002/cncr.30191 |doi-access=free |pmid=27434055}}</ref> A soft tissue [[sarcoma]] is often a painless mass that grows slowly over months or years. They may be superficial or deep-seated. Any such unexplained mass must be diagnosed by [[biopsy]].<ref name="Ferri"/> Treatment may include, [[surgery]], [[radiotherapy]], [[chemotherapy]], and [[Targeted therapy|targeted drug therapy]].<ref name="STS">{{cite web |title=Treating Soft Tissue Sarcomas |url=https://www.cancer.org/cancer/soft-tissue-sarcoma/treating.html |website=www.cancer.org |access-date=1 August 2020 |language=en}}</ref> The other type of sarcoma is a [[bone sarcoma]].
A '''soft-tissue sarcoma''' ('''STS''') is a [[Malignancy|malignant]] [[tumor]], a type of [[cancer]], that develops in [[soft tissue]].<ref name="Ratan">{{cite journal |last1=Ratan |first1=R |last2=Patel |first2=SR |title=Chemotherapy for soft tissue sarcoma. |journal=Cancer |date=October 2016 |volume=122 |issue=19 |pages=2952–60 |doi=10.1002/cncr.30191 |doi-access=free |pmid=27434055}}</ref> A soft-tissue [[sarcoma]] is often a painless mass that grows slowly over months or years. They may be superficial or deep-seated. Any such unexplained mass must be diagnosed by [[biopsy]].<ref name="Ferri"/> Treatment may include [[surgery]], [[radiotherapy]], [[chemotherapy]], and [[Targeted therapy|targeted drug therapy]].<ref name="STS">{{cite web |title=Treating Soft Tissue Sarcomas |url=https://www.cancer.org/cancer/soft-tissue-sarcoma/treating.html |website=www.cancer.org |access-date=1 August 2020 |language=en}}</ref> [[Bone sarcoma]]s are the other class of sarcomas.


There are many types. The [[World Health Organization]] lists more than fifty subtypes.<ref name="CRUK">{{cite web |title=Types of soft tissue sarcoma {{!}} Cancer Research UK |url=https://about-cancer.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types?_ga=2.43167143.322311465.1569566414-876143559.1415373757 |website=about-cancer.cancerresearchuk.org |access-date=27 September 2019}}</ref><ref name="Ferri">{{cite book |last1=Ferri |first1=Fred |title=Ferri's clinical advisor 2019 : 5 books in 1 |date=2019 |publisher=Elsevier |isbn=9780323530422 |page=1219}}</ref>
There are many different types, many of which are rarely found.<ref name="CRUK">{{cite web |title=Types of soft tissue sarcoma {{!}} Cancer Research UK |url=https://about-cancer.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types?_ga=2.43167143.322311465.1569566414-876143559.1415373757 |website=about-cancer.cancerresearchuk.org |access-date=27 September 2019}}</ref> The [[World Health Organization]] lists more than fifty subtypes.<ref name="Ferri">{{cite book |last1=Ferri |first1=Fred |title=Ferri's clinical advisor 2019 : 5 books in 1 |date=2019 |publisher=Elsevier |isbn=9780323530422 |page=1219}}</ref>


==Types==
==Types==
{| class="wikitable plainrowheaders"
{| class="wikitable plainrowheaders"
|+ Table 1: Major Types of Soft-Tissue Sarcomas in Adults
|+ Table 1: Major types of soft-tissue sarcomas in adults
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="col" | Tissue of Origin
! scope="col" | Tissue of origin
! scope="col" | Type of Cancer
! scope="col" | Type of cancer
! scope="col" | Usual Location in the Body
! scope="col" | Usual location in the body
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=3 | Fibrous tissue
! scope="row" style="text-align: left;" rowspan=3 | Fibrous tissue
| [[Undifferentiated pleomorphic sarcoma]] (UPS)
| [[Fibrosarcoma]]
| Arms, legs, trunk
|- style="vertical-align: top;"
| [[Malignant fibrous histiocytoma|Malignant fibrous hystiocytoma]]
| Legs
| Legs
|- style="vertical-align: top;"
|- style="vertical-align: top;"
| [[Dermatofibrosarcoma]]
| [[Dermatofibrosarcoma protuberans]]
| Trunk
| Trunk
|-
|[[Synovial sarcoma]]
|Legs
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Fat
! scope="row" style="text-align: left;" | Fat
Line 58: Line 58:
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=2 | Blood vessels
! scope="row" style="text-align: left;" rowspan=2 | Blood vessels
| [[Hemangiosarcoma]]
| [[Angiosarcoma]]
| Arms, legs, trunk
| Arms, legs, trunk, radiated tissues
|- style="vertical-align: top;"
|- style="vertical-align: top;"
| [[Kaposi's sarcoma]] || Legs, trunk
| [[Kaposi's sarcoma|Kaposi sarcoma]] || Legs, trunk
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Lymph vessels
! scope="row" style="text-align: left;" | Lymph vessels
| [[Lymphangiosarcoma]]
| [[Angiosarcoma]]
| Arms
| Arms
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Synovial tissue{{efn|name=synovial}}
| [[Synovial sarcoma]]
| Legs
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Peripheral nerves
! scope="row" style="text-align: left;" | Peripheral nerves
| [[Malignant peripheral nerve sheath tumour]] / [[Neurofibrosarcoma]]
| [[Malignant peripheral nerve sheath tumor]] / [[Neurofibrosarcoma]]
| Arms, legs, trunk
| Arms, legs, trunk
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=2 | Cartilage and bone-forming tissue
! scope="row" style="text-align: left;" rowspan=2 | Cartilage and bone-forming tissue
| Extraskeletal [[chondrosarcoma]]
| Extraskeletal myxoid [[chondrosarcoma]]
| Legs
| Legs
|- style="vertical-align: top;"
|- style="vertical-align: top;"
Line 83: Line 79:


{| class="wikitable plainrowheaders"
{| class="wikitable plainrowheaders"
|+ Table 2: Major Types of Soft-Tissue Sarcomas in Children
|+ Table 2: Major types of soft-tissue sarcomas in children
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="col" | Tissue of Origin
! scope="col" | Tissue of origin
! scope="col" | Type of Cancer
! scope="col" | Type of cancer
! scope="col" | Usual Location in the Body
! scope="col" | Most common locations in the body
! scope="col" | Most common ages
! scope="col" | Most common ages
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=3 | Muscle (striated)
! rowspan="2" scope="row" style="text-align: left;" | Muscle (striated)
| Embryonal and Alveolar rhabdomyosarcoma
| Rhabdomyosarcoma
|Head and neck, genitourinary tract
|
|Infant–6
|
|- style="vertical-align: top;"
| Embryonal
| Head and neck, genitourinary tract
| Infant–4
|- style="vertical-align: top;"
|- style="vertical-align: top;"
| [[Alveolar soft part sarcoma]]
| [[Alveolar soft part sarcoma]]
| Arms, legs, head, and neck
| Arms, legs, head, and neck
| 10–19
| Infant–19
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Muscle (smooth)
! scope="row" style="text-align: left;" | Muscle (smooth)
| Leiomyosarcoma
| Leiomyosarcoma
| Trunk
| Trunk
| 15–19
| 15-35+
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=3| Fibrous tissue
! rowspan="3" scope="row" style="text-align: left;" | Fibrous tissue
| Undifferentiated pleomorphic sarcoma
| Fibrosarcoma
| Arms and legs
| 15–19
|- style="vertical-align: top;"
| Malignant fibrous histiocytoma
| Legs
| Legs
| 15–19
| 15–19+
|- style="vertical-align: top;"
|- style="vertical-align: top;"
| Dermatofibrosarcoma
| Dermatofibrosarcoma protuberans
| Trunk
| Trunk
| 15–19
| 15–19
|- style="vertical-align: top;"
| Synovial sarcoma
| Legs, arms, and trunk
| 15–35
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Fat
! scope="row" style="text-align: left;" | Fat
| Liposarcoma
| Liposarcoma
| Arms and Legs
| Arms and Legs
| 15–19
| 15–19+
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Blood vessels
| Infantile hemangio-pericytoma
| Arms, legs, trunk, head, and neck
| Infant–4
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Synovial tissue{{efn|name=synovial}}
| Synovial sarcoma
| Legs, arms, and trunk
| 15–19
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Peripheral nerves
! scope="row" style="text-align: left;" | Peripheral nerves
| Malignant peripheral nerve sheath tumors (also called neurofibrosarcomas, malignant schwannomas, and neurogenic sarcomas)
| Malignant peripheral nerve sheath tumors (also called neurofibrosarcomas)
| Arms, legs, and trunk
| Arms, legs, and trunk
| 15–19
| 15–19+
|- style="vertical-align: top;"
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" | Muscular nerves
! scope="row" style="text-align: left;" | Cartilage and bone-forming tissue
| [[Alveolar soft part sarcoma]]
| Arms and legs
| Infant–19
|- style="vertical-align: top;"
! scope="row" style="text-align: left;" rowspan=2 | Cartilage and bone-forming tissue
| [[Extraskeletal myxoid chondrosarcoma]]
| [[Extraskeletal myxoid chondrosarcoma]]
| Legs
| Legs
| 10–14
| 15-35
|}''An earlier version of this article was taken from the [[United States|US]] [[National Cancer Institute|National Cancer Center]]'s Cancer Information Service. The names of several sarcomas have changed over time.''
|- style="vertical-align: top;"
| Extraskeletal mesenchymal
| Legs
| 10–14
|}
{{notelist|refs=
{{efn|name=synovial|Linings of joint cavities, tendon sheaths}}
}}


== Signs and symptoms ==
''An earlier version of this article was taken from the [[United States|US]] [[National Cancer Institute|National Cancer Center]]'s Cancer Information Service.''
In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.<ref name=":0">{{Cite journal |last1=Gronchi |first1=A. |last2=Miah |first2=A. B. |last3=Dei Tos |first3=A. P. |last4=Abecassis |first4=N. |last5=Bajpai |first5=J. |last6=Bauer |first6=S. |last7=Biagini |first7=R. |last8=Bielack |first8=S. |last9=Blay |first9=J. Y. |last10=Bolle |first10=S. |last11=Bonvalot |first11=S. |last12=Boukovinas |first12=I. |last13=Bovee |first13=J. V. M. G. |last14=Boye |first14=K. |last15=Brennan |first15=B. |date=2021 |title=Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ |journal=Annals of Oncology|volume=32 |issue=11 |pages=1348–1365 |doi=10.1016/j.annonc.2021.07.006 |issn=1569-8041 |pmid=34303806|doi-access=free |hdl=2318/1795615 |hdl-access=free }}</ref>


== Risk factors ==
==Signs and symptoms==
In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.{{Citation needed|date=July 2008}}

==Risk factors==
Most soft-tissue sarcomas are not associated with any known risk factors or identifiable cause. There are some exceptions:
Most soft-tissue sarcomas are not associated with any known risk factors or identifiable cause. There are some exceptions:


*Studies suggest that workers who are exposed to [[chlorophenol]]s in wood preservatives and [[phenoxy herbicide]]s may have an increased risk of developing soft-tissue sarcomas. An unusual percentage of patients with a rare blood vessel tumor, [[angiosarcoma]] of the liver, have been exposed to [[vinyl chloride]] in their work. This substance is used in the manufacture of certain plastics, notably [[polyvinyl chloride|PVC]].<ref>{{Cite news|url=http://www.cancercenter.com/soft-tissue-sarcoma/risk-factors/|title=Soft Tissue Sarcoma Risk Factors {{!}} CTCA|work=CancerCenter.com|access-date=2017-04-07}}</ref>
*Studies suggest that workers who are exposed to [[chlorophenol]]s in wood preservatives and [[phenoxy herbicide]]s may have a somewhat increased risk of developing soft-tissue sarcomas, although other data sets refute this association. An small number of patients with a rare blood vessel tumor, [[angiosarcoma]] of the liver, had been exposed to [[vinyl chloride]] in their work. This substance is used in the manufacture of certain plastics, notably [[polyvinyl chloride|PVC]].<ref>{{Cite news|url=http://www.cancercenter.com/soft-tissue-sarcoma/risk-factors/|title=Soft Tissue Sarcoma Risk Factors {{!}} CTCA|work=CancerCenter.com|access-date=2017-04-07|archive-date=2017-11-01|archive-url=https://web.archive.org/web/20171101095725/http://www.cancercenter.com/soft-tissue-sarcoma/risk-factors/|url-status=dead}}</ref>
*In the early 1900s, when scientists were just discovering the potential uses of [[radiation]] to treat disease, little was known about safe dosage levels and precise methods of delivery. At that time, radiation was used to treat a variety of noncancerous medical problems, including enlargement of the tonsils, adenoids, and thymus gland. Later, researchers found that high doses of radiation caused soft-tissue sarcomas in some patients.{{citation needed|date=August 2020}} Because of this risk, radiation treatment for cancer is now planned to ensure that the maximum dosage of radiation is delivered to diseased tissue while surrounding healthy tissue is protected as much as possible.{{Citation needed|date=July 2008}}
*In the early 1900s, when scientists were just discovering the potential uses of [[radiation]] to treat disease, little was known about safe dosage levels and precise methods of delivery. At that time, radiation was used to treat a variety of noncancerous medical problems, including enlargement of the tonsils, adenoids, and thymus gland. Later, researchers found that high doses of radiation caused soft-tissue sarcomas in some patients.<ref>{{Cite web |date=2023-10-31 |title=Radiation-Induced Second Malignancies: Understanding Risks and Improving Detection - AmericanHealthblog.com |url=https://americanhealthblog.com/index.php/2023/10/31/radiation-induced-second-malignancies-understanding-risks-and-improving-detection/ |access-date=2023-10-31 |language=en-GB}}</ref> Because of this risk, radiation treatment for cancer is now planned to ensure that the maximum dosage of radiation is delivered to diseased tissue while surrounding healthy tissue is protected as much as possible.<ref name=":0" />
*[[Kaposi's sarcoma]], a rare cancer of the cells that line blood vessels in the skin and mucus membranes, is caused by [[human herpesvirus 8]]. Kaposi's sarcoma often occurs in patients with [[AIDS|acquired immune deficiency syndrome]]. Kaposi's sarcoma, however, has different characteristics than typical soft-tissue sarcomas and is treated differently.{{Citation needed|date=July 2008}}
*[[Kaposi's sarcoma|Kaposi sarcoma]], a rare cancer of the cells that line blood vessels in the skin and mucous membranes, is caused by [[human herpesvirus 8]]. Kaposi sarcoma often occurs in patients with [[AIDS|acquired immune deficiency syndrome]]. Kaposi sarcoma, however, has different characteristics from typical soft-tissue sarcomas and is treated differently.<ref>{{Cite journal |last1=Lebbe |first1=Celeste |last2=Garbe |first2=Claus |last3=Stratigos |first3=Alexander J. |last4=Harwood |first4=Catherine |last5=Peris |first5=Ketty |last6=Marmol |first6=Veronique Del |last7=Malvehy |first7=Josep |last8=Zalaudek |first8=Iris |last9=Hoeller |first9=Christoph |last10=Dummer |first10=Reinhard |last11=Forsea |first11=Ana Maria |last12=Kandolf-Sekulovic |first12=Lidija |last13=Olah |first13=Judith |last14=Arenberger |first14=Petr |last15=Bylaite-Bucinskiene |first15=Matilda |date=2019 |title=Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC) |journal=European Journal of Cancer |volume=114 |pages=117–127 |doi=10.1016/j.ejca.2018.12.036 |issn=1879-0852 |pmid=31096150|doi-access=free }}</ref>
*In a very small fraction of cases, sarcoma may be related to a rare inherited genetic alteration of the ''[[p53]]'' gene and is known as [[Li-Fraumeni syndrome]]. Certain other [[inherited diseases]] are associated with an increased risk of developing soft-tissue sarcomas. For example, people with [[neurofibromatosis type I]] (also called von Recklinghausen's disease, associated with alterations in the ''NF1 ''gene) are at an increased risk of developing soft-tissue sarcomas known as malignant peripheral nerve-sheath tumors. Patients with inherited retinoblastoma have alterations in the ''RB1 ''gene, a tumor-suppressor gene, and are likely to develop soft-tissue sarcomas as they mature into adulthood.
*In a very small fraction of cases, sarcoma may be related to a rare inherited genetic alteration of the ''[[p53|TP53]]'' gene and is known as [[Li-Fraumeni syndrome]]. Certain other [[inherited diseases]] are associated with an increased risk of developing soft-tissue sarcomas. For example, people with [[neurofibromatosis type I]] (also called von Recklinghausen disease, associated with alterations in the ''NF1 ''gene) are at an increased risk of developing soft-tissue sarcomas known as malignant peripheral nerve-sheath tumors. Patients with inherited retinoblastoma have alterations in the ''RB1 ''gene, a tumor-suppressor gene, and are likely to develop soft-tissue sarcomas as they mature into adulthood.

==Diagnosis==
The only reliable way to determine whether a soft-tissue tumour is benign or malignant is through a biopsy. The two methods for acquisition of tumour tissue for [[Cytopathology|cytopathological]] analysis are:
*[[Needle aspiration biopsy]], via [[Hypodermic needle|needle]]
*Surgically, via an incision made into the tumour
A pathologist examines the tissue under a microscope. If cancer is present, the pathologist can usually determine the type of cancer and its [[Grading (tumors)|grade]]. Here, 'grade' refers to a scale used to represent concisely the predicted growth rate of the tumour and its tendency to spread, and this is determined by the degree to which the cancer cells appear abnormal when examined under a microscope. Low-grade sarcomas, although cancerous, are defined as those that are less likely to [[metastasis]]e. High-grade sarcomas are defined as those more likely to spread to other parts of the body.
For soft-tissue sarcoma, the two histological grading systems are the National Cancer Institute system and the French Federation of Cancer Centers Sarcoma Group system.<ref>{{cite journal |title=Grading of soft tissue sarcomas: from histological to molecular assessment. |year=2014 |journal=Pathology |doi=10.1097/PAT.0000000000000048 |author=Neuvill |display-authors=etal |pmid=24378389 |volume=46 |issue=2 |pages=113–20|s2cid=13436450 |url=https://semanticscholar.org/paper/22569fecef8ae7ba6bcca039730e2cf7e33c18eb }}</ref><ref name="pmid17090186">{{cite journal |author=Coindre JM |title=Grading of soft tissue sarcomas: review and update |journal=Arch. Pathol. Lab. Med. |volume=130|issue=10|pages=1448–53|year=2006 |pmid=17090186 |doi=10.5858/2006-130-1448-GOSTSR|url=https://www.archivesofpathology.org/doi/full/10.1043/1543-2165%282006%29130%5B1448%3AGOSTSR%5D2.0.CO%3B2}}</ref><ref>[http://www.bmc.com.lb/PDF_Files/Grading%20of%20Bone%20&%20Soft%20Tissue%20Sarcomas.pdf Grading of Bone & Soft Tissue Sarcomas. Tawil. 2016](inc details of French system)</ref>


== Diagnosis ==
Soft-tissue sarcomas commonly originate in the upper body, in the shoulder or upper chest. Some symptoms are uneven posture, pain in the trapezius muscle, and [[Neck|cervical]] inflexibility [difficulty in turning the head].{{Citation needed|date=July 2008}}
The only reliable way to determine whether a soft-tissue tumor is benign or malignant is through a biopsy. The two methods for acquisition of tumor tissue for [[Cytopathology|cytopathological]] analysis are:
*[[Needle aspiration biopsy]], via [[Hypodermic needle|needle]]
*Surgically, via an incision made into the tumor
A pathologist examines the tissue under a microscope. The pathologist may be the most important person in the treatment of sacomas, because they are responsible for making the proper diagnosis. Pathologists at expert sarcoma centers are invaluable in identifying the type of sarcoma responsible for a patient's symptoms. If cancer is present, the pathologist can usually determine the type of cancer and its [[Grading (tumors)|grade]]. Here, ''grade'' refers to a scale used to represent concisely the predicted growth rate of the tumor and its tendency to spread, and this is determined by the degree to which the cancer cells appear abnormal when examined under a microscope. Low-grade sarcomas, although cancerous, are defined as those that are less likely to [[metastasis]]e. High-grade sarcomas are defined as those more likely to spread to other parts of the body. For soft-tissue sarcoma, the two histological grading systems are the National Cancer Institute system and the French Federation of Cancer Centers Sarcoma Group system.<ref>{{cite journal |title=Grading of soft tissue sarcomas: from histological to molecular assessment. |year=2014 |journal=Pathology |doi=10.1097/PAT.0000000000000048 |author=Neuvill |display-authors=etal |pmid=24378389 |volume=46 |issue=2 |pages=113–20|s2cid=13436450 }}</ref><ref name="pmid17090186">{{cite journal |author=Coindre JM |title=Grading of soft tissue sarcomas: review and update |journal=Arch. Pathol. Lab. Med. |volume=130|issue=10|pages=1448–53|year=2006 |pmid=17090186 |doi=10.5858/2006-130-1448-GOSTSR|url=https://www.archivesofpathology.org/doi/full/10.1043/1543-2165%282006%29130%5B1448%3AGOSTSR%5D2.0.CO%3B2}}</ref><ref>[http://www.bmc.com.lb/PDF_Files/Grading%20of%20Bone%20&%20Soft%20Tissue%20Sarcomas.pdf Grading of Bone & Soft Tissue Sarcomas. Tawil. 2016] {{Webarchive|url=https://web.archive.org/web/20161220100759/http://bmc.com.lb/PDF_Files/Grading%20of%20Bone%20%26%20Soft%20Tissue%20Sarcomas.pdf |date=2016-12-20 }}(inc details of French system)</ref>


Soft-tissue sarcomas commonly originate in the upper body, in the shoulder or upper chest. Some symptoms are uneven posture, pain in the trapezius muscle, and [[Neck|cervical]] inflexibility [difficulty in turning the head].<ref>{{Cite journal |last1=Dyrop |first1=Heidi B. |last2=Vedsted |first2=Peter |last3=Safwat |first3=Akmal |last4=Maretty-Nielsen |first4=Katja |last5=Hansen |first5=Bjarne H. |last6=Jørgensen |first6=Peter H. |last7=Baad-Hansen |first7=Thomas |last8=Keller |first8=Johnny |date=2014 |title=Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center |journal=Acta Orthopaedica |volume=85 |issue=6 |pages=657–662 |doi=10.3109/17453674.2014.957086 |issn=1745-3682 |pmc=4259033 |pmid=25175662}}</ref> The most common site to which soft-tissue sarcoma spreads is the lungs.<ref name=":1">{{Cite journal |last1=Brennan |first1=Murray F. |last2=Antonescu |first2=Cristina R. |last3=Moraco |first3=Nicole |last4=Singer |first4=Samuel |date=2014 |title=Lessons learned from the study of 10,000 patients with soft tissue sarcoma |journal=Annals of Surgery |volume=260 |issue=3 |pages=416–421; discussion 421–422 |doi=10.1097/SLA.0000000000000869 |issn=1528-1140 |pmc=4170654 |pmid=25115417}}</ref>
The most common site to which soft-tissue sarcoma spreads is the lungs.{{Citation needed|date=July 2010}}


==Treatment==
== Treatment ==
In general, treatment for soft-tissue sarcomas depends on the stage of the cancer. The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include [[surgery]], [[radiotherapy]], [[chemotherapy]], and targeted drug therapy.<ref name="STS"/>
In general, treatment for soft-tissue sarcomas depends on the stage of the cancer. The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include [[surgery]], [[radiotherapy]], [[chemotherapy]], and targeted drug therapy.<ref name="STS"/>


* Surgery is the most common treatment for soft-tissue sarcomas. The tumour is removed leaving a safe margin of surrounding healthy tissue to decrease the chances of its recurrence.
* Surgery is the most common treatment for soft-tissue sarcomas, and usually the only way to achieve a cure. The tumor is removed leaving a safe margin of surrounding healthy tissue to decrease the chances of its recurrence.
* [[Radiation therapy]] may be used as a [[neoadjuvant therapy|neoadjuvant]] before surgery to shrink tumours, or as an [[Adjuvant therapy|adjuvant]] after surgery to kill any cancer cells that may have been left behind. In some cases, it can be used to treat tumours that cannot be surgically removed.
* [[Radiation therapy]] may be used as a [[neoadjuvant therapy|neoadjuvant]] before surgery to shrink tumors, or as an [[Adjuvant therapy|adjuvant]] after surgery to kill any cancer cells that may have been left behind. In some cases, it can be used to treat tumor that cannot be surgically removed.
* [[Chemotherapy]] may be used with radiation therapy either before or after surgery to try to shrink the tumor or kill any remaining cancer cells. There is evidence to suggest that [[doxorubicin]] chemotherapy as an adjuvant can reduce recurrence at the original site or elsewhere in the body.<ref name="Cochrane">{{Cite journal|date=2000-10-23|title=Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.cd001419|issn=1465-1858|pmc=8078558}}</ref> Evidence also suggests chemotherapy can increase the length of time patients live, but this is less certain evidence. The use of chemotherapy to prevent the spread of soft-tissue sarcomas has not been proven to be effective. If the cancer has spread to other areas of the body, chemotherapy may be used to shrink tumors and reduce the pain and discomfort they cause, but is unlikely to eradicate the disease.
* [[Chemotherapy]] may be used with radiation therapy either before or after surgery to try to shrink the tumor or kill any remaining cancer cells. There is evidence to suggest that [[doxorubicin]] chemotherapy as an adjuvant can reduce recurrence at the original site or elsewhere in the body.<ref name="Cochrane">{{Cite journal|date=2000-10-23|title=Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.cd001419|issn=1465-1858|pmc=8078558|author1=Sarcoma Meta-analysis Collaboration (SMAC) - see acknowledgement section for list of authors |volume=2000 |issue=4 |pages=CD001419 }}</ref> Evidence also suggests chemotherapy can increase the length of time patients live, but this is less certain evidence. The use of chemotherapy to prevent the spread of soft-tissue sarcomas has not been proven to be effective. If the cancer has spread to other areas of the body, chemotherapy may be used to shrink tumors and reduce the pain and discomfort they cause, but is unlikely to eradicate the disease. A combination of [[docetaxel]] and [[gemcitabine]] could be an effective chemotherapy regimen in patients with advanced soft-tissue sarcoma.<ref>{{cite web |url=http://professional.cancerconsultants.com/oncology_sarcoma_cancer_news.aspx?id=36670 |title=Oncology Sarcoma Cancer News |access-date=2010-06-15 |url-status=dead |archive-url=https://web.archive.org/web/20101210025537/http://professional.cancerconsultants.com/oncology_sarcoma_cancer_news.aspx?id=36670 |archive-date=2010-12-10 }}</ref><ref>[http://theoncologist.alphamedpress.org/content/12/8/999.full Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future. 2007](free full text)</ref>
* Outcomes are better for patients who are seen (and ideally treated) at expert sarcoma centers.<ref>{{Cite journal |last1=Blay |first1=J.-Y. |last2=Honoré |first2=C. |last3=Stoeckle |first3=E. |last4=Meeus |first4=P. |last5=Jafari |first5=M. |last6=Gouin |first6=F. |last7=Anract |first7=P. |last8=Ferron |first8=G. |last9=Rochwerger |first9=A. |last10=Ropars |first10=M. |last11=Carrere |first11=S. |last12=Marchal |first12=F. |last13=Sirveaux |first13=F. |last14=Di Marco |first14=A. |last15=Le Nail |first15=L. R. |date=2019-07-01 |title=Surgery in reference centers improves survival of sarcoma patients: a nationwide study |journal=Annals of Oncology|volume=30 |issue=7 |pages=1143–1153 |doi=10.1093/annonc/mdz124 |issn=1569-8041 |pmc=6637376 |pmid=31081028}}</ref> In the United States, these are generally found in NCI-designated cancer centers.[https://www.cancer.gov/research/infrastructure/cancer-centers]
:A combination of [[docetaxel]] and [[gemcitabine]] could be an effective chemotherapy regimen in patients with advanced soft-tissue sarcoma.<ref>{{cite web |url=http://professional.cancerconsultants.com/oncology_sarcoma_cancer_news.aspx?id=36670 |title=Archived copy |access-date=2010-06-15 |url-status=dead |archive-url=https://web.archive.org/web/20101210025537/http://professional.cancerconsultants.com/oncology_sarcoma_cancer_news.aspx?id=36670 |archive-date=2010-12-10 }}</ref><ref>[http://theoncologist.alphamedpress.org/content/12/8/999.full Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future. 2007](free full text)</ref>


==Research==
==Research==
The research in soft tissue sarcoma requires lot of effort because of its rarity and needs immense collaboration. In year 2019, few notable researches have been presented but mostly failed. However, we are learning that they can't be lumped together and each sarcoma is a different disease.<ref>{{cite journal |last1=Rastogi |first1=Sameer |last2=Manasa |first2=Parisa |last3=Kalra |first3=Kaushal |display-authors=etal |date=2019 |title=Advances in soft-tissue sarcoma – There are no mistakes, only lessons<!--space omitted in original, included in PMC etc. versions--> to learn! |journal=South Asian Journal of Cancer |volume=8 |issue=4 |pages=258–259 |doi=10.4103/sajc.sajc_215_19 |pmc=6852635 |pmid=31807494 }}</ref>
Soft-tissue sarcoma research requires significant effort due to its rarity; successful research requires substantial collaboration. Year by year, the medical field is learning that the various types cannot be lumped together and each sarcoma needs to be considered a different type of cancer.<ref>{{cite journal |last1=Rastogi |first1=Sameer |last2=Manasa |first2=Parisa |last3=Kalra |first3=Kaushal |display-authors=etal |date=2019 |title=Advances in soft-tissue sarcoma – There are no mistakes, only lessons<!--space omitted in original, included in PMC etc. versions--> to learn! |journal=South Asian Journal of Cancer |volume=8 |issue=4 |pages=258–259 |doi=10.4103/sajc.sajc_215_19 |pmc=6852635 |pmid=31807494 |doi-access=free }}</ref>


Immunotherapy may have an upcoming role in treating soft tissue sarcomas like alveolar soft part sarcoma and pleomorphic undifferentiated sarcoma. In a report by Dr. Sameer Rastogi et al, a patient with advanced pleomorphic undifferentiated sarcoma had excellent response to combination of pembrolizumab and pazopanib.<ref>{{cite journal |last1=Arora |first1=Shalabh |last2=Rastogi |first2=Sameer |last3=Shamim |first3=Shamim Ahmed |last4=Barwad |first4=Adarsh |last5=Sethi |first5=Maansi |title=Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report |journal=Clinical Sarcoma Research |date=9 July 2020 |volume=10 |issue=1 |page=10 |doi=10.1186/s13569-020-00133-9 |pmc=7346343 |pmid=32670543}}</ref>
As a novel form of treatment used in other cancers, immunotherapy may have an role in treating soft-tissue sarcomas like alveolar soft part sarcoma and pleomorphic undifferentiated sarcoma. However, as of 2023, only alveolar soft part sarcoma has a regulatory approval for such an agent, in this case atezolizumab.<ref>{{Cite journal |last=Research |first=Center for Drug Evaluation and |date=2022-12-09 |title=FDA grants approval to atezolizumab for alveolar soft part sarcoma |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-approval-atezolizumab-alveolar-soft-part-sarcoma |journal=FDA |language=en}}</ref>


=== Example of sarcoma immunology research: the Immunological Constant of Rejection ===
==Epidemiology==
When the [[Immunologic Constant of Rejection|immunological constant of rejection signature (ICR)]] was retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables; thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients’ age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative/qualitative scores of immune response. ICR1 class was associated with a 59% increased risk of metastatic relapse when compared with ICR2-4 class. In multivariate analysis, ICR classification remained associated with metastasis-free survival, as well as pathological type and Complexity Index in Sarcomas (CINSARC) classification, suggesting independent prognostic value.<ref name="Bertucci">{{cite journal |last1=Bertucci |first1=F |last2=Niziers |first2=V |last3=de Nonneville |first3=A |last10=Ceccarelli et al.|title=Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. |journal=Journal for Immunotherapy of Cancer |date=January 2022 |volume=10 |issue=1 |pages=e003687 |doi=10.1136/jitc-2021-003687 |pmid=35017155|pmc=8753443 }}</ref>
Soft-tissue sarcomas are relatively uncommon cancers. They account for less than 1% of all new cancer cases each year. This may be because cells in soft tissue, in contrast to tissues that more commonly give rise to malignancies, are not [[Labile cell|continuously dividing cells]].{{Citation needed|date=July 2008}}


ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. A robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.<ref name="Bertucci"/>
In 2006, about 9,500 new cases were diagnosed in the United States.<ref>Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute, 2006.</ref> Soft-tissue sarcomas are more commonly found in older patients (>50 years old), although in children and adolescents under age 20, certain histologies are common ([[rhabdomyosarcoma]], [[synovial sarcoma]]).{{Citation needed|date=July 2008}}

== Epidemiology ==
Soft-tissue sarcomas are very uncommon cancers. They account for less than 1% of all new cancer cases each year.<ref name=":2">{{Cite journal |last1=Siegel |first1=Rebecca L. |last2=Miller |first2=Kimberly D. |last3=Wagle |first3=Nikita Sandeep |last4=Jemal |first4=Ahmedin |date=January 2023 |title=Cancer statistics, 2023 |journal=CA: A Cancer Journal for Clinicians |volume=73 |issue=1 |pages=17–48 |doi=10.3322/caac.21763 |issn=1542-4863 |pmid=36633525|doi-access=free }}</ref>

In 2023, about 14,300 new cases were diagnosed in the United States.<ref name=":2" /> Soft-tissue sarcomas are more commonly found in older patients (>50 years old), although in children and adolescents under age 20, certain histologies are common ([[rhabdomyosarcoma]], [[synovial sarcoma]]).<ref name=":1" />


Around 3,300 people were diagnosed with soft-tissue sarcoma in the UK in 2011.<ref>{{cite web|title=Soft tissue sarcoma statistics|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/soft-tissue-sarcoma/|website=Cancer Research UK|access-date=28 October 2014}}</ref>
Around 3,300 people were diagnosed with soft-tissue sarcoma in the UK in 2011.<ref>{{cite web|title=Soft tissue sarcoma statistics|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/soft-tissue-sarcoma/|website=Cancer Research UK|access-date=28 October 2014}}</ref>


==Notable cases==
== Notable cases ==
*Actor [[Robert Urich]] died from [[synovial sarcoma]].
* Actor [[Robert Urich]] died from [[synovial sarcoma]].<ref>{{Cite web |date=2002-04-16 |title=Robert Urich Loses Cancer Fight |url=https://www.cbsnews.com/news/robert-urich-loses-cancer-fight/ |access-date=2023-05-07 |website=[[CBS News]]}}</ref>
* Folksinger [[Kate McGarrigle]] died from [[clear-cell sarcoma]].<ref>[https://www.nytimes.com/2010/01/20/arts/music/20mcgarrigle.html "Kate McGarrigle, Canadian Singer and Songwriter, Dies at 63"]; ''[[The New York Times]],'' Jan. 20, 2010</ref>
*Actress [[Michelle Thomas]] died from [[desmoplastic small-round-cell tumor]], a rare abdominal soft-tissue sarcoma.
* Actress [[Michelle Thomas]] died from [[desmoplastic small-round-cell tumor]], a rare abdominal soft-tissue sarcoma.<ref>{{Cite web |title=Celebrities With Stomach Cancer |url=https://www.webmd.com/cancer/ss/slideshow-celebrities-gastric-cancer |access-date=2023-05-07 |website=WebMD |language=en}}</ref>
*[[It Is Written]] evangelist Henry Feyerabend died from sarcoma in his leg.{{Citation needed|date=July 2011}}
* ''[[It Is Written]]'' evangelist Henry Feyerabend died from sarcoma in his leg.<ref>{{Cite web |date=2021-10-24 |title=Feyerabend, Henry Raymond (1931–2006) |url=https://encyclopedia.adventist.org/article?id=GIB7 |access-date=2023-05-07 |website=Encyclopedia of Seventh Day Adventists}}</ref>
*Video game concept artist [[Adam Adamowicz]] died from complications of a rare muscle sarcoma on Feb. 9, 2012. He was 43.
* Video game concept artist [[Adam Adamowicz]] died from complications of a rare muscle sarcoma on February 9, 2012, at age 42.{{Citation needed|date=May 2023}}
*Professional wrestler [[Jake Roberts]] revealed he has muscle cancer.
*Professional wrestler [[Zack Ryder]] revealed he suffered from [[synovial sarcoma]] as a teenager.<ref>{{Cite web | url=http://www.wwe.com/inside/the-scars-of-the-superstars/page-13 | title=The scars of the Superstars}}</ref>
* Professional wrestler [[Jake Roberts]] revealed he has muscle cancer.{{Citation needed|date=May 2023}}
* Professional wrestler [[Zack Ryder]] revealed he had [[synovial sarcoma]] as a teenager.<ref>{{Cite web |title=The scars of the Superstars |url=https://www.wwe.com/node/26355169/page-13 |access-date=2023-05-07 |website=WWE |language=en}}</ref>
* India's Ex Finance Minister [[Arun Jaitley]] died due to this disease on 24 August 2019.
* India's ex-finance minister [[Arun Jaitley]] died from sarcoma on August 24, 2019.<ref>{{Cite web |last=Phelamei |first=Salome |date=2019-08-24 |title=Arun Jaitley was treated for a rare type of cancer: What is soft tissue sarcoma? Symptoms, causes, treatment |url=https://www.timesnownews.com/health/article/arun-jaitley-was-treated-for-a-rare-type-of-cancer-what-is-soft-tissue-sarcoma-symptoms-causes-treatment/348940 |access-date=2023-05-07 |website=[[Times Now News]]}}</ref>
* Writer [[Rachel Caine]] died from the disease on November 1 2020
* Writer [[Rachel Caine]] died from the disease on November 1, 2020.<ref>{{Cite web |last= |date=2020-11-02 |title=In Memoriam - Rachel Caine |url=https://www.sfwa.org/2020/11/02/in-memoriam-rachel-caine/ |access-date=2023-05-07 |website=[[Science Fiction and Fantasy Writers Association]]}}</ref>
* YouTuber [[Technoblade]] died from the disease in June, 2022.<ref>{{Cite web |last=Saunders |first=Cindy |date=2022-09-28 |title=Technoblade To Be Honored by SFA with Courage Award |url=https://www.curesarcoma.org/technoblade-courage-award-at-new-york-gala/ |access-date=2023-05-07 |website=[[Sarcoma Foundation of America]]}}</ref>

== See also ==

* [[Soft tissue sarcoma in cats and dogs]]


==References==
== References ==
{{Reflist}}
{{Reflist}}


Revision as of 09:35, 17 July 2024

Soft-tissue sarcoma
Undifferentiated soft tissue sarcoma in left lung of young child
SpecialtyOncology Edit this on Wikidata

A soft-tissue sarcoma (STS) is a malignant tumor, a type of cancer, that develops in soft tissue.[1] A soft-tissue sarcoma is often a painless mass that grows slowly over months or years. They may be superficial or deep-seated. Any such unexplained mass must be diagnosed by biopsy.[2] Treatment may include surgery, radiotherapy, chemotherapy, and targeted drug therapy.[3] Bone sarcomas are the other class of sarcomas.

There are many different types, many of which are rarely found.[4] The World Health Organization lists more than fifty subtypes.[2]

Types

Table 1: Major types of soft-tissue sarcomas in adults
Tissue of origin Type of cancer Usual location in the body
Fibrous tissue Undifferentiated pleomorphic sarcoma (UPS) Legs
Dermatofibrosarcoma protuberans Trunk
Synovial sarcoma Legs
Fat Liposarcoma Arms, legs, trunk
Muscle (striated) Rhabdomyosarcoma Arms, legs
Muscle (smooth) Leiomyosarcoma Uterus, digestive tract
Blood vessels Angiosarcoma Arms, legs, trunk, radiated tissues
Kaposi sarcoma Legs, trunk
Lymph vessels Angiosarcoma Arms
Peripheral nerves Malignant peripheral nerve sheath tumor / Neurofibrosarcoma Arms, legs, trunk
Cartilage and bone-forming tissue Extraskeletal myxoid chondrosarcoma Legs
Extraskeletal osteosarcoma Legs, trunk (not involving the bone)
Table 2: Major types of soft-tissue sarcomas in children
Tissue of origin Type of cancer Most common locations in the body Most common ages
Muscle (striated) Embryonal and Alveolar rhabdomyosarcoma Head and neck, genitourinary tract Infant–6
Alveolar soft part sarcoma Arms, legs, head, and neck 10–19
Muscle (smooth) Leiomyosarcoma Trunk 15-35+
Fibrous tissue Undifferentiated pleomorphic sarcoma Legs 15–19+
Dermatofibrosarcoma protuberans Trunk 15–19
Synovial sarcoma Legs, arms, and trunk 15–35
Fat Liposarcoma Arms and Legs 15–19+
Peripheral nerves Malignant peripheral nerve sheath tumors (also called neurofibrosarcomas) Arms, legs, and trunk 15–19+
Cartilage and bone-forming tissue Extraskeletal myxoid chondrosarcoma Legs 15-35

An earlier version of this article was taken from the US National Cancer Center's Cancer Information Service. The names of several sarcomas have changed over time.

Signs and symptoms

In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.[5]

Risk factors

Most soft-tissue sarcomas are not associated with any known risk factors or identifiable cause. There are some exceptions:

  • Studies suggest that workers who are exposed to chlorophenols in wood preservatives and phenoxy herbicides may have a somewhat increased risk of developing soft-tissue sarcomas, although other data sets refute this association. An small number of patients with a rare blood vessel tumor, angiosarcoma of the liver, had been exposed to vinyl chloride in their work. This substance is used in the manufacture of certain plastics, notably PVC.[6]
  • In the early 1900s, when scientists were just discovering the potential uses of radiation to treat disease, little was known about safe dosage levels and precise methods of delivery. At that time, radiation was used to treat a variety of noncancerous medical problems, including enlargement of the tonsils, adenoids, and thymus gland. Later, researchers found that high doses of radiation caused soft-tissue sarcomas in some patients.[7] Because of this risk, radiation treatment for cancer is now planned to ensure that the maximum dosage of radiation is delivered to diseased tissue while surrounding healthy tissue is protected as much as possible.[5]
  • Kaposi sarcoma, a rare cancer of the cells that line blood vessels in the skin and mucous membranes, is caused by human herpesvirus 8. Kaposi sarcoma often occurs in patients with acquired immune deficiency syndrome. Kaposi sarcoma, however, has different characteristics from typical soft-tissue sarcomas and is treated differently.[8]
  • In a very small fraction of cases, sarcoma may be related to a rare inherited genetic alteration of the TP53 gene and is known as Li-Fraumeni syndrome. Certain other inherited diseases are associated with an increased risk of developing soft-tissue sarcomas. For example, people with neurofibromatosis type I (also called von Recklinghausen disease, associated with alterations in the NF1 gene) are at an increased risk of developing soft-tissue sarcomas known as malignant peripheral nerve-sheath tumors. Patients with inherited retinoblastoma have alterations in the RB1 gene, a tumor-suppressor gene, and are likely to develop soft-tissue sarcomas as they mature into adulthood.

Diagnosis

The only reliable way to determine whether a soft-tissue tumor is benign or malignant is through a biopsy. The two methods for acquisition of tumor tissue for cytopathological analysis are:

A pathologist examines the tissue under a microscope. The pathologist may be the most important person in the treatment of sacomas, because they are responsible for making the proper diagnosis. Pathologists at expert sarcoma centers are invaluable in identifying the type of sarcoma responsible for a patient's symptoms. If cancer is present, the pathologist can usually determine the type of cancer and its grade. Here, grade refers to a scale used to represent concisely the predicted growth rate of the tumor and its tendency to spread, and this is determined by the degree to which the cancer cells appear abnormal when examined under a microscope. Low-grade sarcomas, although cancerous, are defined as those that are less likely to metastasise. High-grade sarcomas are defined as those more likely to spread to other parts of the body. For soft-tissue sarcoma, the two histological grading systems are the National Cancer Institute system and the French Federation of Cancer Centers Sarcoma Group system.[9][10][11]

Soft-tissue sarcomas commonly originate in the upper body, in the shoulder or upper chest. Some symptoms are uneven posture, pain in the trapezius muscle, and cervical inflexibility [difficulty in turning the head].[12] The most common site to which soft-tissue sarcoma spreads is the lungs.[13]

Treatment

In general, treatment for soft-tissue sarcomas depends on the stage of the cancer. The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include surgery, radiotherapy, chemotherapy, and targeted drug therapy.[3]

  • Surgery is the most common treatment for soft-tissue sarcomas, and usually the only way to achieve a cure. The tumor is removed leaving a safe margin of surrounding healthy tissue to decrease the chances of its recurrence.
  • Radiation therapy may be used as a neoadjuvant before surgery to shrink tumors, or as an adjuvant after surgery to kill any cancer cells that may have been left behind. In some cases, it can be used to treat tumor that cannot be surgically removed.
  • Chemotherapy may be used with radiation therapy either before or after surgery to try to shrink the tumor or kill any remaining cancer cells. There is evidence to suggest that doxorubicin chemotherapy as an adjuvant can reduce recurrence at the original site or elsewhere in the body.[14] Evidence also suggests chemotherapy can increase the length of time patients live, but this is less certain evidence. The use of chemotherapy to prevent the spread of soft-tissue sarcomas has not been proven to be effective. If the cancer has spread to other areas of the body, chemotherapy may be used to shrink tumors and reduce the pain and discomfort they cause, but is unlikely to eradicate the disease. A combination of docetaxel and gemcitabine could be an effective chemotherapy regimen in patients with advanced soft-tissue sarcoma.[15][16]
  • Outcomes are better for patients who are seen (and ideally treated) at expert sarcoma centers.[17] In the United States, these are generally found in NCI-designated cancer centers.[1]

Forschung

Soft-tissue sarcoma research requires significant effort due to its rarity; successful research requires substantial collaboration. Year by year, the medical field is learning that the various types cannot be lumped together and each sarcoma needs to be considered a different type of cancer.[18]

As a novel form of treatment used in other cancers, immunotherapy may have an role in treating soft-tissue sarcomas like alveolar soft part sarcoma and pleomorphic undifferentiated sarcoma. However, as of 2023, only alveolar soft part sarcoma has a regulatory approval for such an agent, in this case atezolizumab.[19]

Example of sarcoma immunology research: the Immunological Constant of Rejection

When the immunological constant of rejection signature (ICR) was retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables; thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients’ age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative/qualitative scores of immune response. ICR1 class was associated with a 59% increased risk of metastatic relapse when compared with ICR2-4 class. In multivariate analysis, ICR classification remained associated with metastasis-free survival, as well as pathological type and Complexity Index in Sarcomas (CINSARC) classification, suggesting independent prognostic value.[20]

ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. A robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.[20]

Epidemiology

Soft-tissue sarcomas are very uncommon cancers. They account for less than 1% of all new cancer cases each year.[21]

In 2023, about 14,300 new cases were diagnosed in the United States.[21] Soft-tissue sarcomas are more commonly found in older patients (>50 years old), although in children and adolescents under age 20, certain histologies are common (rhabdomyosarcoma, synovial sarcoma).[13]

Around 3,300 people were diagnosed with soft-tissue sarcoma in the UK in 2011.[22]

Notable cases

See also

References

  1. ^ Ratan, R; Patel, SR (October 2016). "Chemotherapy for soft tissue sarcoma". Cancer. 122 (19): 2952–60. doi:10.1002/cncr.30191. PMID 27434055.
  2. ^ a b Ferri, Fred (2019). Ferri's clinical advisor 2019 : 5 books in 1. Elsevier. p. 1219. ISBN 9780323530422.
  3. ^ a b "Treating Soft Tissue Sarcomas". www.cancer.org. Retrieved 1 August 2020.
  4. ^ "Types of soft tissue sarcoma | Cancer Research UK". about-cancer.cancerresearchuk.org. Retrieved 27 September 2019.
  5. ^ a b Gronchi, A.; Miah, A. B.; Dei Tos, A. P.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J. Y.; Bolle, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J. V. M. G.; Boye, K.; Brennan, B. (2021). "Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆". Annals of Oncology. 32 (11): 1348–1365. doi:10.1016/j.annonc.2021.07.006. hdl:2318/1795615. ISSN 1569-8041. PMID 34303806.
  6. ^ "Soft Tissue Sarcoma Risk Factors | CTCA". CancerCenter.com. Archived from the original on 2017-11-01. Retrieved 2017-04-07.
  7. ^ "Radiation-Induced Second Malignancies: Understanding Risks and Improving Detection - AmericanHealthblog.com". 2023-10-31. Retrieved 2023-10-31.
  8. ^ Lebbe, Celeste; Garbe, Claus; Stratigos, Alexander J.; Harwood, Catherine; Peris, Ketty; Marmol, Veronique Del; Malvehy, Josep; Zalaudek, Iris; Hoeller, Christoph; Dummer, Reinhard; Forsea, Ana Maria; Kandolf-Sekulovic, Lidija; Olah, Judith; Arenberger, Petr; Bylaite-Bucinskiene, Matilda (2019). "Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)". European Journal of Cancer. 114: 117–127. doi:10.1016/j.ejca.2018.12.036. ISSN 1879-0852. PMID 31096150.
  9. ^ Neuvill; et al. (2014). "Grading of soft tissue sarcomas: from histological to molecular assessment". Pathology. 46 (2): 113–20. doi:10.1097/PAT.0000000000000048. PMID 24378389. S2CID 13436450.
  10. ^ Coindre JM (2006). "Grading of soft tissue sarcomas: review and update". Arch. Pathol. Lab. Med. 130 (10): 1448–53. doi:10.5858/2006-130-1448-GOSTSR. PMID 17090186.
  11. ^ Grading of Bone & Soft Tissue Sarcomas. Tawil. 2016 Archived 2016-12-20 at the Wayback Machine(inc details of French system)
  12. ^ Dyrop, Heidi B.; Vedsted, Peter; Safwat, Akmal; Maretty-Nielsen, Katja; Hansen, Bjarne H.; Jørgensen, Peter H.; Baad-Hansen, Thomas; Keller, Johnny (2014). "Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center". Acta Orthopaedica. 85 (6): 657–662. doi:10.3109/17453674.2014.957086. ISSN 1745-3682. PMC 4259033. PMID 25175662.
  13. ^ a b Brennan, Murray F.; Antonescu, Cristina R.; Moraco, Nicole; Singer, Samuel (2014). "Lessons learned from the study of 10,000 patients with soft tissue sarcoma". Annals of Surgery. 260 (3): 416–421, discussion 421–422. doi:10.1097/SLA.0000000000000869. ISSN 1528-1140. PMC 4170654. PMID 25115417.
  14. ^ Sarcoma Meta-analysis Collaboration (SMAC) - see acknowledgement section for list of authors (2000-10-23). "Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults". Cochrane Database of Systematic Reviews. 2000 (4): CD001419. doi:10.1002/14651858.cd001419. ISSN 1465-1858. PMC 8078558.
  15. ^ "Oncology Sarcoma Cancer News". Archived from the original on 2010-12-10. Retrieved 2010-06-15.
  16. ^ Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future. 2007(free full text)
  17. ^ Blay, J.-Y.; Honoré, C.; Stoeckle, E.; Meeus, P.; Jafari, M.; Gouin, F.; Anract, P.; Ferron, G.; Rochwerger, A.; Ropars, M.; Carrere, S.; Marchal, F.; Sirveaux, F.; Di Marco, A.; Le Nail, L. R. (2019-07-01). "Surgery in reference centers improves survival of sarcoma patients: a nationwide study". Annals of Oncology. 30 (7): 1143–1153. doi:10.1093/annonc/mdz124. ISSN 1569-8041. PMC 6637376. PMID 31081028.
  18. ^ Rastogi, Sameer; Manasa, Parisa; Kalra, Kaushal; et al. (2019). "Advances in soft-tissue sarcoma – There are no mistakes, only lessons to learn!". South Asian Journal of Cancer. 8 (4): 258–259. doi:10.4103/sajc.sajc_215_19. PMC 6852635. PMID 31807494.
  19. ^ Research, Center for Drug Evaluation and (2022-12-09). "FDA grants approval to atezolizumab for alveolar soft part sarcoma". FDA.
  20. ^ a b Bertucci, F; Niziers, V; de Nonneville, A (January 2022). "Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature". Journal for Immunotherapy of Cancer. 10 (1): e003687. doi:10.1136/jitc-2021-003687. PMC 8753443. PMID 35017155.
  21. ^ a b Siegel, Rebecca L.; Miller, Kimberly D.; Wagle, Nikita Sandeep; Jemal, Ahmedin (January 2023). "Cancer statistics, 2023". CA: A Cancer Journal for Clinicians. 73 (1): 17–48. doi:10.3322/caac.21763. ISSN 1542-4863. PMID 36633525.
  22. ^ "Soft tissue sarcoma statistics". Cancer Research UK. Retrieved 28 October 2014.
  23. ^ "Robert Urich Loses Cancer Fight". CBS News. 2002-04-16. Retrieved 2023-05-07.
  24. ^ "Kate McGarrigle, Canadian Singer and Songwriter, Dies at 63"; The New York Times, Jan. 20, 2010
  25. ^ "Celebrities With Stomach Cancer". WebMD. Retrieved 2023-05-07.
  26. ^ "Feyerabend, Henry Raymond (1931–2006)". Encyclopedia of Seventh Day Adventists. 2021-10-24. Retrieved 2023-05-07.
  27. ^ "The scars of the Superstars". WWE. Retrieved 2023-05-07.
  28. ^ Phelamei, Salome (2019-08-24). "Arun Jaitley was treated for a rare type of cancer: What is soft tissue sarcoma? Symptoms, causes, treatment". Times Now News. Retrieved 2023-05-07.
  29. ^ "In Memoriam - Rachel Caine". Science Fiction and Fantasy Writers Association. 2020-11-02. Retrieved 2023-05-07.
  30. ^ Saunders, Cindy (2022-09-28). "Technoblade To Be Honored by SFA with Courage Award". Sarcoma Foundation of America. Retrieved 2023-05-07.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Soft-tissue_sarcoma&oldid=1235023427"